2. シグナル伝達
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CCR

CCR

CC chemokine receptor

CCR

Related Products

PDF 0.04 MB

CCR (Chemokine receptors) are cytokine receptors found on the surface of certain cells that interact with a type of cytokine called achemokine. There have been 19 distinct chemokine receptors described in mammals. Each has a 7-transmembrane (7TM) structure and couples to G-protein for signal transduction within a cell, making them members of a large protein family of G protein-coupled receptors. Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux in intracellular calcium (Ca2+) ions (calcium signaling). This causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to a desired location within the organism. Chemokine receptors are divided into different families, CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors and XC chemokine receptors that correspond to the 4 distinct subfamilies of chemokines they bind. Specific chemokine receptors provide the portals for HIV to get into cells, and others contribute to inflammatory diseases and cancer.

CCR Isoform Specific Products:

CCR Isoform Comparison
製品番号 製品名 製品効果 純度 構造式
  • HY-136788
    ALK4290 Inhibitor 99.79%
    ALK4290 (AKST4290) is a potent, orally active and selective CCR3 inhibitor with a Ki of 3.2 nM. ALK4290 blocks CCR3-mediated signaling, abrogates macrophage supernatant-driven mesothelial-to-mesenchymal transition, and decreases p38 phosphorylation. ALK4290 inhibits CCL26-CCR3 axis-driven GPX2-mediated B-cell activation, and targets B cells to inhibit activation by GPX2-overexpressing tumor cells. ALK4290 can be used for the research of hepatocellular carcinome and Parkinson’s disease.
    ALK4290
  • HY-P991061
    Tagmokitug Inhibitor 99.9%
    Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (Kd = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatory T cells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8+ T cell subsets. Tagmokitug can be used for the research of solid tumors.
    Tagmokitug
  • HY-148100A
    Emapticap pegol sodium Inhibitor
    Emapticap pegol sodium is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol sodium is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36).
    Emapticap pegol sodium
  • HY-148100
    Emapticap pegol Inhibitor
    Emapticap pegol (NOX-E36) is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36). mNOX-E36 is a murine-specific analogue of NOX-E36, an anti-MCP-1 L-RNA aptamer that was previously shown to attenuate liver fibrosis in mice.
    Emapticap pegol
  • HY-402739
    CCR2-IN-1 Inhibitor
    CCR2-IN-1 (Compound HO11553-TM) is a G protein-coupled receptor CCR2 inhibitor. CCR2-IN-1 slows the progression of idiopathic pulmonary fibrosis. CCR2-IN-1 can be used for the research of idiopathic pulmonary fibrosis.
    CCR2-IN-1
  • HY-P99474
    Bertilimumab Inhibitor
    Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research.
    Bertilimumab
  • HY-111069
    Nifeviroc Inhibitor 99.39%
    Nifeviroc is an orally active CCR5 antagonist. Nifeviroc is used for the study of HIV type-1 infection.
    Nifeviroc
  • HY-13499
    JNJ-41443532 Inhibitor 99.65%
    JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM). JNJ-41443532 displays a Ki of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease.
    JNJ-41443532
  • HY-P991224
    CAP-100 Inhibitor 99.84%
    CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL.
    CAP-100
  • HY-P991481
    S-531011 Inhibitor 98.38%
    S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8+ regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma.
    S-531011
  • HY-P990982
    Denrakibart Inhibitor 98.24%
    HY-P990982 is an CCL17-targeting IgG2κ type human antibody, the recommed isotype control is Human IgG2 kappa, Isotype Control (HY-P99002).
    Denrakibart
  • HY-145491
    Resolvin D5 Inhibitor 98.3%
    Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis.
    Resolvin D5
  • HY-P991481A
    S-531011 (FUT8-KO) Inhibitor
    S-531011 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. S-531011 (FUT8-KO) can be used for the research of cancer immunity.
    S-531011 (FUT8-KO)
  • HY-RS02163
    CCR6 Human Pre-designed siRNA Set A Inhibitor

    CCR6 Human Pre-designed siRNA Set A contains three designed siRNAs for CCR6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CCR6 Human Pre-designed siRNA Set A
  • HY-P992120
    Minokitug Inhibitor
    Minokitug is a humanized monoclonal antibody targeting the CCR2 protein. Minokitug can be used for the research of refractory/relapsed ulcerative colitis.
    Minokitug
  • HY-P11553B
    DOTA-ECL1i Inhibitor 98.06%
    DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer.
    DOTA-ECL1i
  • HY-P991942
    Lanerkitug Inhibitor
    Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8+ Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors.
    Lanerkitug
  • HY-19501
    DPC-168 Inhibitor
    DPC-168 is an orally effective CCR3 antagonist (IC50 = 41 nM). DPC-168 exhibits a significant ability to inhibit eosinophil chemotaxis and pulmonary inflammation. DPC-168 can be used for research on airway inflammation.
    DPC-168
  • HY-103406A
    PNU-177864 hydrochloride Inhibitor
    PNU-177864 is a potent, selective, orally active dopamine D3 receptor antagonist. PNU-177864 induces phospholipid metabolism in vivo and has anti-schizophrenia activity.
    PNU-177864 hydrochloride
  • HY-152132
    CCR5 antagonist 3 Inhibitor
    CCR5 antagonist 3 (Compound 26) is a CCR5 antagonist with an IC50 of 15.90 nM. CCR5 antagonist 3 shows broad-spectrum anti-HIV-1 activities.
    CCR5 antagonist 3
製品番号 製品名 / Synonyms Species Source
製品番号 製品名 / Synonyms Application Reactivity
CCR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.